Teresa Macarulla

Sobre mí

Publicaciones destacadas

• Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors.

  Autores:

  Castet F; Tian TV; Macarulla T;

  Referencia: ANNALS OF ONCOLOGY 2025.

• Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer

  Autores:

  Castet, Florian; Fabregat-Franco, Carles; Bridgewater, John; Kim, Jin Won; Rimini, Margherita;

  (...)

  Casadei-Gardini, Andrea; DURVABTC Grp; Yoo, Changhoon; Valle, JUan W; Macarulla, Teresa.

  Ver listado completo de autores

  Referencia: JOURNAL OF HEPATOLOGY 2025.

• A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX.

  Autores:

  Álvarez-Gallego R; Macarulla T; Laquente B; Peinado P; Castet F;

  (...)

  Sanz-García E; Toledano C; Quijano Y; Vicente E; Cubillo A.

  Ver listado completo de autores

  Referencia: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 2025.

• Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

  Autores:

  Babiker, Hani M; Picozzi, Vincent; Chandana, Sreenivasa R; Melichar, Bohuslav; Kasi, Anup;

  (...)

  Philip, Philip; Ueno, Makoto; Van Cutsem, Eric; Seufferlein, Thomas; Macarulla, Teresa.

  Ver listado completo de autores

  Referencia: JOURNAL OF CLINICAL ONCOLOGY 2025.

• Genomic profiling unlocks new treatment opportunities for ampullary carcinoma

  Autores:

  Fabregat-Franco, C; Castet, F; Castillo, G; Salcedo, M; Sierra, A;

  Lopez-Valbuena, D; Pando, E; Tian, T V; Macarulla, T.

  Referencia: ESMO Open 2025.

• Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

  Autores:

  Macarulla, Teresa; Ren, Zhenggang; Chon, Hong Jae; Park, Joon Oh; Kim, Jin Won;

  (...)

  Liu, Bo; Guan, Xiangnan; Lu, Shan; Wang, Yulei; El-Khoueiry, Anthony B.

  Ver listado completo de autores

  Referencia: JOURNAL OF CLINICAL ONCOLOGY 2025.

• Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

  Autores:

  Melisi D; Macarulla T; De La Fouchardière C; Pazo Cid RA; Chandana SR;

  (...)

  Maxwell F; Zhang L; Benzaghou F; O'Reilly EM; Wainberg ZA.

  Ver listado completo de autores

  Referencia: ESMO Open 2025.

• Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

  Autores:

  Gonzalez-Medina, Alberto; Vila-Casadesus, Maria; Gomez-Rey, Marina; Fabregat-Franco, Carles; Sierra, Alexandre;

  (...)

  Miquel, Josep M; Nuciforo, Paolo; Perez-Lopez, Raquel; Macarulla, Teresa; Vivancos, Ana.

  Ver listado completo de autores

  Referencia: CLINICAL CANCER RESEARCH 2024.

• Facts and Hopes in the Systemic Therapy of Biliary Tract Carcinomas

  Autores:

  Lamarca, Angela; Macarulla, Teresa;

  Referencia: CLINICAL CANCER RESEARCH 2024.

• Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

  Autores:

  Bockorny, Bruno; Macarulla, Teresa; Semenisty, Valerya; Borazanci, Erkut; Feliu, Jaime;

  (...)

  Ickowicz, Debby; Sorani, Ella; Kadosh, Shaul; Vainstein-Haras, Abi; Hidalgo, Manuel.

  Ver listado completo de autores

  Referencia: CLINICAL CANCER RESEARCH 2021.

Proyectos destacados

• Early-Onset Pancreatic Ductal Adenocarcinoma: A Comprehensive Multimodal Investigation (EOPC-ACMI)

  Investigador/a principal: Teresa Macarulla Mercadé

  Financiador: Asociación Española Contra el Cáncer (AECC)

  Duración: 01/01/2025 - 01/01/2029

• COMBinATorial Personalized Approaches for Subtyping and Targeting Functional Heterogeneity in Pancreatic Ductal AdenoCarcinoma (COMBATPDAC). EP PerMed

  Investigador/a principal: Teresa Macarulla Mercadé

  Financiador: European Partnership for Personalized Medicine

  Código: AC24/00045

  Duración: 01/01/2025 - 01/01/2027

• Pronóstico de Recurrencia Temprana Después de la Cirugía en Adenocarcinoma Ductal Pancreático Resecable y Borderline Resecable mediante Análisis Multi-Ómico

  Investigador/a principal: Teresa Macarulla Mercadé

  Financiador: Instituto de Salud Carlos III (ISCIII)

  Código: PI24/00526

  Duración: 01/01/2025 - 01/01/2027

• TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, therapias avanzadas y medicina de sistemes

  Investigador/a principal: Begoña Benito Villabriga

  Financiador: Instituto de Salud Carlos III (ISCIII)

  Código: FORT23/00034

  Duración: 01/01/2024 - 01/01/2028

• Exploring the Feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors (Immune4ALL)

  Investigador/a principal: Enrique de Alava

  Financiador: Instituto de Salud Carlos III (ISCIII)

  Código: PMP22/00054

  Duración: 01/01/2023 - 01/01/2026